RATES OF OPIOID OVERDOSE
have increased since the early 1990s because of lower-cost, higher-purity heroin and prescription opioid abuse. [1] [2] [3] [4] [5] In Massachusetts, from 1990 to 2006, annual opioid overdose-related fatalities increased over 6-fold, from 94 to 637. 6, 7 In response, the Boston Public Health Commission (BPHC) passed a regulation that authorized the development of an overdose prevention program with naloxone distribution through its mobile needle-exchange program. This program is innovative, because it includes the distribution of intranasal naloxone by trained, nonmedical public health workers to potential overdose bystanders for administration to overdose victims. Legal and regulatory barriers to implementation are detailed in the box on page 791. Naloxone, an opioid antagonist, reverses opioid overdose by displacing opioid agonists, such as heroin or oxycodone, from Administering naloxone hydrochloride (naloxone) during an opioid overdose reverses the overdose and can prevent death. Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device. In August 2006, the Boston Public Health Commission passed a public health regulation that authorized an opioid overdose prevention program that included intranasal naloxone education and distribution of the spray to potential bystanders. Participants were taught by trained nonmedical needle exchange staff. After 15 months, the program provided training and intranasal naloxone to 385 participants who reported 74 successful overdose reversals. Problems with intranasal naloxone were uncommon. Overdose prevention education with distribution of intranasal naloxone is a feasible public health intervention to address opioid overdose. FIELD ACTION REPORT °T he BPHC started an overdose prevention program with intranasal naloxone distribution as a result of the successful experience of the city's emergency medical services use of the nasal spray as a prehospital treatment for opioid overdose; the concept was also seen as an attractive option because intranasal delivery of the drug eliminates the risks of needlestick injuries and needle disposal. BPHC implemented the program through the needle-exchange program because program participants were considered particularly likely to witness overdoses.
PROGRAM CURRICULUM
All participating needle-exchange program staff-2 nurses and 4 nonmedical public health workers-completed 8 hours of didactic training, a knowledge test, and at least 4 supervised bystander-training sessions. Both the staff training and bystander training were adapted from existing program curricula from other cities that primarily used needlebased naloxone. 8, 14, [17] [18] [19] [20] [21] The 15-minute bystander training included techniques in overdose prevention. Staff completed a checklist (available as a supplement to the online article at http://www.ajph.org) to ensure participant comprehension. Overdose prevention kits included instructions; 2 luer-lock, prefilled opioid receptors. It is the standard treatment used by medical personnel. It has no abuse potential, and its only contraindication is a prior allergic reaction, which is rare. 8 Although typically administered intravenously or intramuscularly, it can be administered intranasally. [9] [10] [11] [12] [13] Strong interest in overdose prevention training and access to naloxone exists among potential overdose bystanders, including family members 14 and drug-using partners. 15 Overdose prevention programs with naloxone distribution that train and distribute naloxone to people who are likely to witness an overdose have been successfully implemented in several communities, including Chicago, 16, 17 New York, 18, 19 San Francisco, 20 Baltimore, 15, 21 and New Mexico. 8 A 6-program study demonstrated that trained bystanders were similarly skilled as medical experts in recognizing opioid overdose situations, and when naloxone was indicated. 22 
KEY FINDINGS
■ Needle-exchange participants have experienced and witnessed high rates of overdoses.
■ Needle-exchange participants can successfully recognize an overdose and use intranasal naloxone to reverse potentially fatal opioid overdoses.
■ With the support and regulation of the local public health authority, overdose prevention programs can provide training and distribute intranasal naloxone without a direct clinical health care provider-patient encounter.
■ Overdose prevention programs that include the distribution of intranasal naloxone by nonmedical personnel are feasible for city public health departments.
FIELD ACTION REPORT °° FIELD ACTION REPORT °s yringes with 2 mg/2 mL naloxone hydrochloride; and the mucosal atomization device. Participants were instructed to deliver 1 mL (1 mg) to each nostril of the overdose victim. Because most opioid agonists have a longer halflife than naloxone, if overdose symptoms returned, victims could be treated with the second dose. previous overdose, the median number of lifetime overdoses was 2, and among the 303 (92%) who had witnessed an overdose, the median number of lifetime witnessed overdoses was 5. Follow-up contact was made at least once with 278 (72%) participants, 222 of whom reported no overdoses witnessed and no need for additional doses of naloxone. Among the 57 participants who requested additional doses, 7 had the naloxone lost, stolen, or confiscated, and 50 administered naloxone while observing an overdose ( Figure  1 ). Among the 50 participants (13%) who reported reversing an overdose, 74 successful reversals were reported. Except for mean age (43 vs 39 years; P < .05), there were no significant differences between those participants who reported reversing an overdose and those who did not (data not shown). Emergency medical personnel were involved in 21 of the 74 (28%) reported overdoses and were not involved in 39 (53%) reported overdoses. Involvement by emergency medical personnel was not reported in the remainder (data available as a supplement to the online article at http://www.ajph. org). Two previous studies of naloxone distribution programs have reported similar rates of emergency medical personnel involvement (10% to 31%). 20, 23 Among follow-up contacts, problems were uncommon. During 4 overdoses, bystanders could not connect the mucosal atomization device to the syringe, although each resulted in successful reversal. Two administered naloxone nasally directly from the syringe, 1 injected the naloxone intramuscularly, and 1 did not administer naloxone, but delivered rescue breathing and physical stimulation until Boston Emergency Medical Services arrived. Two bystanders reported that naloxone induced withdrawal symptoms, but, in both cases, the victim did not use additional opioids to alleviate symptoms. Two bystanders observed the naloxone wearing off: 1 readministered it after 90 minutes, and 1 reported that the victim became resedated after 20 minutes, when Boston Emergency Medical Services assumed care. Two people had naloxone confiscated at a homeless shelter, 1 reported being expelled from a residential drug treatment program for having the substance, and 3 reported negative interactions with emergency medical personnel, FIELD ACTION REPORT °° FIELD ACTION REPORT °J ohn Townsend, General Counsel of the BPHC.
DATA COLLECTION AND ANALYSIS

Human Participant Protection
This study was approved as an exempt study by the Boston University Medical Center institutional review board. Of the 74 reported reversals, 4 reports were of bystanders not initially enrolled in the program who used intranasal naloxone obtained from peers who were enrolled. Thus, there was some peer-to-peer overdose knowledge and skill transfer beyond the program.
The BPHC overdose-prevention naloxone distribution program was implemented without substantial additional funding. Space, printing costs, and staff time were provided by the existing needle-exchange program. Naloxone kits cost approximately $25.
NEXT STEPS
The BPHC naloxone distribution program is a feasible, successful program that includes distribution of intranasal naloxone by nonmedical staff. The Massachusetts Department of Public Health has identified overdose prevention as a major focus area for new public health initiatives and has expanded the program to 5 additional sites that target needleexchange participants, staff at substance abuse treatment programs, homeless shelters, and families and friends of opioid users. 
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Barrier Response
Nonmedical personnel are not authorized to distribute prescription medication and are not authorized to administer a prescription medication to a person who has not been prescribed the medication.
• The standard of care for the use of naloxone has for decades included use by prehospital personnel in nonclinical settings operating under standing orders from physicians who are neither on-site nor directly supervising.
• Other life saving prescription medications, such as epinephrine injectors for anaphylactic shock, 24 and other devices, such as automated external defibrillators, are used by bystanders and nonmedical personnel.
• Other states, such as New Mexico, New York and Connecticut, have addressed this by passing laws that limit the liability of medical and nonmedical personnel who administer and distribute potentially lifesaving medication. 25
• A study of 6 programs that train bystanders to recognize and respond to opioid overdose by using naloxone has demonstrated that trained potential bystanders are similarly skilled as medical experts in recognizing opioid overdose situations and when naloxone is indicated. 22 • A local public health regulation was passed by BPHC, the City of Boston's board of health, identifying the overdose-prevention naloxone distribution program as an official public health program and assuming liability for the work of medical and non-medical personnel involved in the program.
• Under the medical license of the Medical Director of Boston Emergency Medical Services, potential bystanders received a standard curriculum about overdose prevention with instructions and demonstration of how to properly use the medication. Receipt of this curriculum was documented by BPHC staff.
Intranasal delivery of naloxone is an off-label method.
• Prescriptions drugs may be and are routinely given for any indication not explicitly prohibited by law. 25, 26 • While no large scale randomized clinical trials have been conducted, intranasal naloxone has been evaluated in several research studies, with little evidence of adverse events. [9] [10] [11] [12] [13] A small randomized trial comparing intranasal with intramuscular delivery of naloxone used by emergency personnel demonstrated that intranasal delivery had a longer time to clinical response (8 minutes vs 6 minutes), but less agitation or irritation (2% vs 13%). 11
• Intranasal naloxone is a first-line treatment for opioid overdose among emergency medical personnel in the local Boston community. 
